Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP19 | O94966 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13442958 | 0.81 | FDPS (0.51) | FDPSTSHROPRL1NLRP3HDAC1 | |
| SCHEMBL4791740 | 0.81 | FDPS (0.51) | FDPSTSHRNLRP3HDAC1HDAC6 | |
| SCHEMBL846777 | 0.81 | FDPS (0.51) | FDPSTSHRNLRP3HDAC1HDAC6 | |
| SCHEMBL4797265 | 0.79 | FDPS (0.50) | FDPSTSHRNLRP3HDAC1HDAC6 | |
| SCHEMBL16029636 | 0.77 | NLRP3 (0.51) | FDPSTSHRNLRP3HDAC1HDAC6 | |
| SCHEMBL18231656 | 0.72 | — | — | |
| SCHEMBL11189962 | 0.72 | — | — | |
| SCHEMBL34468064 | 0.72 | — | — | |
| SCHEMBL2162547 | 0.72 | — | — | |
| SCHEMBL17399639 | 0.72 | CCNC (0.41) | FDPSTSHRHDAC1HDAC6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | PFIZER INC. | 2008-08-21 | — | — | US | claimed |
| CN-101198606-A | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER JAPAN INC (US) | 2008-06-11 | — | — | CN | claimed |
| CN-101198606-A | Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as ORL1-receptor antagonists | PFIZER JAPAN INC (US) | 2008-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200490-A1 | Alpha-(Aryl-or Heteroaryl-Methyl)-Beta-Piperidino Propanamide Compounds as Orl-1-Receptor Antagonists | OPRL1, OPRD1, OGFRL1 | FDPS 4635/4885TSHR 933/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.